ClinicalTrials.gg
Not yet recruitingNCT07184866VITAKI-ACLFUpdated Nov 6, 2026

Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial

An interventional study of Vitamin C and Standard of Care (SOC) in Acute-on-Chronic Liver Failure (ACLF), sponsored by Institute of Liver and Biliary Sciences, India. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Institute of Liver and Biliary Sciences, India · Not applicable, Interventional, and Treatment

How we know

Updated Nov 6, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Acute-On-Chronic Liver Failure by Institute of Liver and Biliary Sciences, India — 17 open to participants now, 17 under way, 2 of them phase 3. Acute-On-Chronic Liver Failure · Institute of Liver and Biliary Sciences, India.

Planned enrollment
12th of 28
110 · median 95
Started
2026
with 3 others
No phase
23 of 39
8 open now
Primary completion
2027-07
later than 10 of 16 live
Registered
38th of 39
by date

Among the 39 studies in Acute-On-Chronic Liver Failure by Institute of Liver and Biliary Sciences, India, this one is the 12th largest by planned enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2026, is one of 23 with no phase, reaches primary completion later than 10 of the 16 other live ones, and was the 38th registered.

Acute-On-Chronic Liver Failure

167 studies on the registry are indexed under Acute-On-Chronic Liver Failure; 61 are open to participants now.

Browse Acute-On-Chronic Liver Failure studies →

Open to participants now

17 of the 39 studies in Acute-On-Chronic Liver Failure by Institute of Liver and Biliary Sciences, India are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 32 Acute-On-Chronic Liver Failure studies recruiting now, 11 (34%) set no upper age limit and 15 (47%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Acute-On-Chronic Liver Failure by Institute of Liver and Biliary Sciences, India, or all of them as a file.
02

Study summary

This study is testing whether Vitamin C can help improve kidney function and survival in very sick patients with liver disease. Patients with acute-on-chronic liver failure (ACLF) often develop serious infections that can lead to septic shock and kidney injury, which are major causes of death.

In this randomized controlled trial, patients with ACLF and septic shock will be assigned to receive either:

  1. Standard medical treatment alone, or
  2. Standard medical treatment plus intravenous Vitamin C.

Vitamin C is a safe, inexpensive antioxidant that may reduce inflammation, improve circulation, and protect the kidneys. The study will compare how well patients recover from septic shock and kidney injury in the two groups. Blood and urine samples will also be collected to look for biological markers that can predict outcomes.

Read the detailed description

Acute-on-chronic liver failure (ACLF) is a severe condition in which patients with chronic liver disease suddenly develop liver failure, often triggered by infection. Many of these patients progress to septic shock, and acute kidney injury (AKI) is a common and life-threatening complication. Current treatment options are limited, and mortality remains very high.

Vitamin C is a low-cost, widely available antioxidant and immune-modulating agent. It has shown promising results in patients with sepsis and septic shock by reducing oxidative stress, improving vascular tone, and supporting immune defense. However, its role in ACLF patients with septic shock and AKI has not been studied in a large, controlled trial.

This interventional, randomized, open-label controlled trial will enroll patients with alcohol-related ACLF, septic shock, and AKI. Participants will be randomized 1:1 to receive either intravenous Vitamin C in addition to standard medical care, or standard care alone. Clinical outcomes, including resolution of shock, progression or resolution of AKI, need for renal replacement therapy, ICU/hospital stay, and survival at 7 and 28 days will be assessed. In addition, biospecimens (blood and urine) will be analyzed to identify biomarkers that predict outcomes and response to Vitamin C therapy.

The study aims to provide evidence on the effectiveness of Vitamin C as an adjunctive therapy in this high-risk population, and to generate insights into the mechanisms of septic shock and kidney injury in ACLF.

03

Conditions studied

  • Acute-on-Chronic Liver Failure (ACLF)

Keywords

  • Sepsis, septic shock, Alcohol-related, ACLF, AKI, Lactate, Vitamin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ACLF as per asia pacific association for the study of liver (APASL criteria) with AKI according to KDIGO Criteria and septic shock.

Exclusion criteria

Exclusion Criteria:

    • Septic shock with more than 3 organ failures.

      • Patients with age less than 18 years
      • Known severe cardiopulmonary disease (structural or valvular heart disease, coronary artery disease, )
      • Patients in DIC with \< 20,000 and > 4 or active bleeding
      • Limitations of care (defined as refusal of cardiovascular and respiratory support modes) including "do not intubate" (DNI) status
      • Current hospitalization > 15 days for patients with nosocomial acquisition of MDR at time of randomization
      • Known allergy or to vitamin C (including previously or currently diagnosed primary hyperoxaluria and/or oxalate nephropathy, or known/suspected ethylene glycol ingestion,
      • Known glucose-6-phosphate dehydrogenase (G6PD) deficiency)
      • Use of vitamin C at a dose of > 1 gram daily within the 24 hours preceding first episode of qualifying organ dysfunction during a given ED or ICU admission
      • Patients with HCC (beyond Milan) or extrahepatic
      • Patients with HVOTO or EHPVO
      • Pregnancy or active breastfeeding
      • Current participation in another interventional research study
      • Active or history of kidney stones
      • History of chronic kidney disease or intrinsic kidney disease
      • Patients already on maintenance hemodialysis prior to presentation
      • Failure to provide
      • Patients with retroviral infection
      • Patients with active hemolysis due to alcohol or other causes or with below 7 gm/dl
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Active comparator
    Standard of Care (SOC)

    Participants in this arm will receive standard medical treatment for ACLF with septic shock and acute kidney injury, as per institutional protocols.

    Other: Standard of Care (SOC)

  • Experimental
    Vitamin C + Standard of Care

    Participants in this arm will receive intravenous Vitamin C (25 mg/kg, up to 1.5 g every 6 hours for 5 days) in addition to standard medical treatment for ACLF with septic shock and acute kidney injury

    Drug: Vitamin C

Interventions

  • DrugAscorbic AcidStudies of Ascorbic AcidAscorbic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous Vitamin C, 25 mg/kg (maximum 1.5 g) every 6 hours for 5 days, administered in addition to standard medical treatment

    Also known as: (Ascorbic Acid)

  • OtherStandard of Care (SOC)

    Supportive and guideline-based management of ACLF with septic shock and AKI, including antibiotics, fluids, vasopressors, renal replacement therapy as required, and other standard therapies

06

What researchers measure

Primary outcomes

  1. Resolution of septic shock at 96 hours (Day 4)

    Resolution of septic shock is defined as maintenance of mean arterial pressure (MAP) ≥ 65 mmHg for ≥ 6 consecutive hours after complete discontinuation of all vasopressor support, without restarting vasopressors during that 6-hour period.

    Time frame: Day 4 (96 hours) after randomization

Secondary outcomes

  1. Outcome of acute kidney injury (AKI) at Day 7

    AKI resolution (decrease in stage by ≥1 or return to no AKI), persistence (same stage), or progression (increase in stage by ≥1 or need for dialysis in stage 3 patients), defined by KDIGO criteria.

    Time frame: Day 7

  2. Incidence of adverse events

    Number and type of adverse events including hypotension, sepsis, bleeding, allergic reactions, anemia, kidney stones, urinary oxalate, hemolysis, and thrombocytopenia.

    Time frame: Day 7, Day 14, Day 28 or until hospital discharge, whichever occurs first

  3. Need for renal replacement therapy

    Proportion of patients requiring initiation of renal replacement therapy.

    Time frame: Day 7

  4. Duration of ICU stay

    Number of days spent in ICU from randomization to discharge or death.

    Time frame: Through hospital discharge or death, up to 28 days

  5. Duration of hospital stay

    Total number of days from admission to discharge or death.

    Time frame: Up to Day 28

  6. 7-day mortality

    All-cause mortality within 7 days of randomization

    Time frame: Day 7

  7. 28-day mortality

    All-cause mortality within 28 days of randomization

    Time frame: Day 28

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jul 2027, 7 months later.

Of 32 interventional studies with no phase under Acute-On-Chronic Liver Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's planned 7 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → Dec 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2025
First posted
Sep 22, 2025
StartEst.
Dec 15, 2026was Apr 2026
Primary completionEst.
Jul 2027
CompletionEst.
Oct 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Apr 2026→Dec 15, 2026
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Start date Apr 2026→Dec 15, 2026
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07184866
Responsible party
Sponsor
First posted
Sep 22, 2025
Start date
Dec 15, 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Dr. Rakhi Maiwall, MBBS, MD, DM
Contact
rakhi_2011@yahoo.co.in
+91 8750343085

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ascorbic Acid

Start the discussion